BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240605T130000
DTEND;TZID=America/New_York:20240605T140000
DTSTAMP:20260405T131710
CREATED:20240513T202047Z
LAST-MODIFIED:20240513T202047Z
UID:65965-1717592400-1717596000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Bayer - Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi®
DESCRIPTION:Date: Wednesday\, June 5\, 2024\nTime: 1:00pm – 2:00pm ET \n\n \nTOPIC:\nClinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi® \nWEBINAR OVERVIEW: \n\nThis session includes key information about Jivi including\, safety and efficacy data from the clinical trials\, step-wise dosing and Jivi RWE Data from the 4th interim analysis of HEM-POWR\, a multinational\, open-label\, prospective\, non-interventional\, multicenter cohort study of Jivi.\nThere will also be a review of the Q2 2024 340B pricing for the Bayer Hemophilia A portfolio under the Hemophilia Alliance Contract.\n\nSPEAKER:\n\nDr. Vanessa K. Salinas-Lunas\nPediatric Hematology\nCenter for Inherited Blood Disorders \nSPEAKER’S BIO:\nN/A
URL:https://hemoalliance.org/alliance-events/a-webinar-from-bayer-clinical-review-of-the-jivi-protect-viii-trial-and-insights-from-hem-powr-a-real-world-evidence-rwe-study-of-jivi/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240610
DTEND;VALUE=DATE:20240613
DTSTAMP:20260405T131710
CREATED:20230908T175404Z
LAST-MODIFIED:20240731T135554Z
UID:45495-1717977600-1718236799@hemoalliance.org
SUMMARY:🟥 Member Event : 2024 Nurses CE Conference
DESCRIPTION:Date: June 10 – 12\nLocation: Portland\, Maine
URL:https://hemoalliance.org/alliance-events/2024-nurses-ce-conference/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240620T140000
DTEND;TZID=America/New_York:20240620T150000
DTSTAMP:20260405T131710
CREATED:20240609T180107Z
LAST-MODIFIED:20240609T180107Z
UID:65966-1718892000-1718895600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts – Practice Considerations for ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) from BioMarin
DESCRIPTION:Date: Thursday\, June 20\, 2024\nTime: 2:00pm – 3:00pm ET \n\n \nTitle: Practice Considerations for ROCTAVIAN™ (valoctocogene roxaparvovec-rvox)  \nObjectives:   \n\n\nReview coverage and typical prior authorization criteria for ROCTAVIAN\n\nReview considerations and pricing education available for single-case agreements\n\nHemophilia Alliance’s gene therapy support for Member Hemophilia Treatment Centers\n\nSpeakers: \n\n\nJosh Sammon\, PharmD\, Senior Director\, Market Access\, Hemophilia\n\nHemophilia Alliance Team
URL:https://hemoalliance.org/alliance-events/a-webinar-on-practice-considerations-for-roctavian-from-biomarin/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240625T130000
DTEND;TZID=America/New_York:20240625T140000
DTSTAMP:20260405T131710
CREATED:20240606T185838Z
LAST-MODIFIED:20240606T185838Z
UID:47764-1719320400-1719324000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts – Wilate Prophylaxis in VWD – Results from the WIL-31 Study from Octapharma
DESCRIPTION:Date: Tuesday\, June 25\, 2024\nTime: 1:00pm – 2:00pm ET \n\n \nTitle: Wilate Prophylaxis in VWD – Results from the WIL-31 Study \nObjectives:\n1) Understand the bleeding symptoms experienced by folks with von Willebrand disease\n2) Understand the benefits of wilate prophylaxis in von Willebrand disease across different ages and types\n3) Understand the lack of von Willebrand factor and FVIII accumulation during wilate prophylaxis  \nSpeaker:\n\nClaudio Sandoval\nSenior Director of Scientific & Medical Affairs at Octapharma \nClaudio Sandoval is the Senior Director of Scientific & Medical Affairs at Octapharma. Before his current role he was a pediatric hematologist-oncologist for 30 years caring for children with bleeding disorders\, cancer\, sickle cell disease\, and other maladies. Claudio graduated from New York Medical College and trained at Schneider Children’s Hospital in New Hyde Park\, NY and St. Jude Children’s Research Hospital in Memphis\, TN.
URL:https://hemoalliance.org/alliance-events/wilate-prophylaxis-in-vwd-results-from-the-wil-31-study-from-octapharma/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR